Skip to main content
TipRanks
Go Ultimate75% OFF

Icon (ICLR) AI Stock Analysis

557 Followers
ICLR

Icon

(NASDAQ:ICLR)

Select Model
Rating:69Neutral
Price Target:$210.00â–²(9.72% Upside)
Action:downgraded
Date:10/29/26

ICLR’s score is primarily supported by solid financial resilience (strong cash generation and manageable leverage) and constructive earnings-call indicators (record bookings and maintained margin outlook). This is offset by weak recent top-line performance and compressed profitability versus prior years, while a strong technical uptrend is tempered by overbought momentum signals and a high P/E valuation with no dividend support.

Positive Factors
Bookings and BacklogRecord bookings and a book-to-bill ratio well above 1x indicate strong demand and support future revenue conversion. The growing backlog and repeated booking momentum improve medium-term planning confidence, reinforce customer relationships, and strengthen ICON’s competitive position in outsourced clinical development.
Negative Factors
Revenue ContractionThe sustained decline in reported revenue indicates that strong bookings have not yet translated into near-term top-line expansion. Continued contraction can pressure operating leverage, reduce the efficiency of the global cost base, and make the company more dependent on successful backlog conversion.

Icon (ICLR) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%ICLR+20.52%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$14.34B
Dividend Yield
―
Average Volume (3M)
976.88K
Price to Earnings (P/E)
32.8
Beta (1Y)
0.88
Revenue Growth
0.67%
EPS Growth
43.70%
Country
US
Employees
40,200
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Icon Business Overview & Revenue Model

Company Description

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, ma...

How the Company Makes Money

ICON primarily makes money by providing fee-based outsourced research and development services to life sciences sponsors. Its revenue model is largely services-driven and tied to sponsor contracts for clinical development and related activities. Key...

Icon Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:4.60%|Next Earnings Date:Jun 23, 2026
Earnings Call SentimentPositive

The call was strongly positive overall. Commercial momentum, record net bookings, sustained book-to-bill performance, margin expansion, cost discipline, cash generation, technology productivity gains, and constructive demand outweighed the year-over-year revenue decline, pass-through volatility, foreign exchange headwind, and expected fourth-quarter SG&A increase.

Positive Updates

Adjusted EBITDA and EPS Growth
Adjusted EBITDA increased 3% sequentially to $337 million, while adjusted EBITDA margin expanded by 70 basis points to 16.6%. Adjusted EPS was $2.66, an increase of 4% compared with Q2.

Negative Updates

Revenue Decline
Q3 revenue was just over $2 billion, representing a year-over-year decrease of 2.9%, or 2.5% on a constant-currency basis. Revenue also decreased 1.9% sequentially, primarily reflecting the divestiture of Symphony.

Company Guidance

For 2026, updated full year guidance reflects higher pass through activity, supporting an increase in the revenue outlook to the high end of the prior range, or about $150 million at the midpoint from where it was before; full year EBITDA margin is expected to be somewhere in the region of 16% to 16.5%, the adjusted effective tax rate approximately 17%, and Q4 SG&A should increase. Pass throughs are currently somewhere in the low thirties, approaching 1 third of revenues approximately, with somewhere in or around that range a reasonable place to think about for next year. The company is not guiding today for 2027, but said it is certainly viable to think about mid single digit revenue expansion next year and maybe higher single digit expansion on earnings, with good execution, meaningful earnings progression, and even at the midpoint another dozen cents or so of earnings expansion quarter over quarter.

Icon Financial Statement Overview

Summary

Solid cash generation and a sturdy, improving balance sheet support the profile (TTM operating cash flow ~$1.54B; debt-to-equity ~0.37). However, the income statement is pressured by a sharp TTM revenue decline (~-21.9%) and margin compression versus 2023–2024, keeping profitability and returns only moderate (TTM net margin ~4.0%; ROE ~4.9%).

Income Statement

62Positive

Balance Sheet

74Positive

Cash Flow

68Positive
Financial statement breakdown
BreakdownTTMMar 2026Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue8.23B8.25B8.28B8.12B7.74B5.48B
Gross Profit1.74B2.18B2.44B2.40B2.21B1.51B
EBITDA1.37B823.57M1.56B1.52B1.37B694.09M
Net Income448.66M229.34M791.47M612.34M505.30M153.19M
Balance Sheet
Total Assets16.24B16.27B16.88B16.99B17.19B17.39B
Cash, Cash Equivalents and Short-Term Investments808.98M647.29M538.78M380.06M290.48M753.92M
Total Debt3.51B3.56B3.60B3.94B4.83B5.65B
Total Liabilities7.12B7.08B7.35B7.75B8.69B9.32B
Stockholders Equity9.13B9.19B9.52B9.24B8.50B8.07B
Cash Flow
Free Cash Flow1.28B861.99M1.12B1.02B421.15M735.39M
Operating Cash Flow1.54B1.04B1.29B1.16B563.32M829.14M
Investing Cash Flow-346.81M-187.53M-266.79M-226.65M-145.87M-6.02B
Financing Cash Flow-926.26M-771.26M-837.18M-844.04M-864.17M5.11B

Icon Technical Analysis

Technical Analysis SentimentPositive
Last Price191.40

Price Trends

50DMA179.55Positive
100DMA173.77Positive
200DMA146.75Positive

Market Momentum

MACD5.86Positive
RSI49.38Neutral
STOCH18.19Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICLR, the sentiment is Positive. The current price of 191.40 is below the 20-day moving average (MA) of 197.74, above the 50-day MA of 179.55, and above the 200-day MA of 146.75, indicating a neutral trend. The MACD of 5.86 indicates Positive momentum. The RSI at 49.38 is Neutral, neither overbought nor oversold. The STOCH value of 18.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ICLR.

Icon Risk Analysis

Icon disclosed 66 risk factors in its most recent earnings report. Icon reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We have concluded that our internal control over financial reporting and our disclosure controls and procedures were not effective as of December 31, 2025 due to material weaknesses, which has adversely affected our ability to report our financial results in a timely and accurate manner and could have a material adverse impact on our business and financial condition.Q4, 2025
2.If we fail to maintain proper and effective internal controls, our business and financial condition could be materially adversely impacted.Q4, 2025
3.Due to inherent limitations, there can be no assurance that our system of disclosure and internal controls and procedures will be successful in preventing all errors, theft and fraud, or in informing management of all material information in a timely manner.Q4, 2025

Icon Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ICLR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MEDPMEDP84Outperform$18.13B35.4799.76%―20.35%25.24%
TMOTMO77Outperform$256.15B36.4013.31%0.27%8.27%9.59%
LHLH75Outperform$30.24B30.3011.54%0.77%6.02%19.63%
IQVIQV74Outperform$43.63B31.8521.82%―8.88%13.11%
ICLRICLR69Neutral$14.34B32.764.85%―0.67%43.70%
CRLCRL62Neutral$16.08B328.751.32%―-1.16%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%ICLRCRLLHTMOIQVMEDPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ICLR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ICLRIcon Plc191.4030.3818.87%
CRLCharles River Laboratories Intl335.52172.99106.44%
LHLabcorp Holdings Inc.372.46115.2544.81%
TMOThermo Fisher Scientific691.33117.3220.44%
IQVIQVIA Holdings264.7347.4521.84%
MEDPMedpace Holdings Inc648.2058.029.83%

Icon Corporate Events

ICON Announces Participation in Jefferies and Evercore Healthcare Conferences

Nov 10, 2026

ICON plc is a clinical research organization serving pharmaceutical, biotechnology, medical-device, government and public-health organizations worldwide. It provides integrated consulting, clinical development, commercialization and post-marketing so...

ICON Restructures Debt, Expands Buybacks and Extends Option Plans

Oct 27, 2026

In July 2026, ICON drew down its $500 million Bridge Secured Credit Facility to repay maturing 2.875% Senior Secured Notes, then fully repaid the bridge facility by August 17, 2026, simplifying near-term debt obligations. On August 13, 2026, a wholly...

ICON plc Posts Strong Q3 2026 Bookings, Refinances Debt With $2.15 Billion Bond

Oct 27, 2026

ICON plc reported third‑quarter 2026 results on October 27, 2026, highlighting strong commercial momentum with net business wins of $3.15 billion, a book‑to‑bill of 1.56x and backlog rising to $24.5 billion. Revenue for the quarter was $2.02 billion,...

ICON plc Sets Dates for Third-Quarter 2026 Earnings Release and Call

Oct 8, 2026

ICON plc announced on October 8, 2026 that it will publish its financial results for the third quarter of 2026 after U.S. market close on Tuesday, October 27, 2026. The company will host a conference call and webcast the following day, Wednesday, Oct...

ICON Files September 2026 Form 6-K With Unaudited Interim Results

Sep 9, 2026

ICON plc, a Dublin-headquartered clinical research organization serving global pharmaceutical and biotech clients, has filed its latest report as a foreign private issuer with the U.S. Securities and Exchange Commission. The company continues to prov...

ICON Showcases 2025 ESG and Innovation Gains in Latest ICON Cares Report

Aug 20, 2026

ICON plc, headquartered in Dublin, Ireland, is a global clinical research organisation that delivers consulting, clinical development, commercialisation and post‑marketing services to pharmaceutical, biotechnology, medical device, government and publ...

ICON plc Raises $2.15 Billion in Senior Notes to Refinance Secured Debt

Aug 18, 2026

On August 13, 2026, ICON Investments Six DAC, a wholly owned subsidiary of ICON plc, issued $2.15 billion of senior unsecured notes in three tranches due 2029, 2031 and 2036, all guaranteed by ICON. The notes were placed privately with institutional...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026